Mail call.
They changed my Infliximab/Remicade pens. The pen itself is more chunky but the needle is supposed to be smaller.
They changed my Infliximab/Remicade pens. The pen itself is more chunky but the needle is supposed to be smaller.
October 12, 2026 at 9:41 AM
Mail call.
They changed my Infliximab/Remicade pens. The pen itself is more chunky but the needle is supposed to be smaller.
They changed my Infliximab/Remicade pens. The pen itself is more chunky but the needle is supposed to be smaller.
Celltrion to Showcase New Studies on ZYMFENTRA® at ACG 2026 Conference#United_States#Ulcerative_Colitis#Crohn's_Disease#Jersey_City#ZYMFENTRA
Celltrion to Showcase New Studies on ZYMFENTRA® at ACG 2026 Conference
Celltrion USA will present new analyses of ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis at ACG 2026. The findings highlight significant clinical outcomes.
third-news.com
October 11, 2026 at 5:11 PM
Celltrion to Showcase New Studies on ZYMFENTRA® at ACG 2026 Conference#United_States#Ulcerative_Colitis#Crohn's_Disease#Jersey_City#ZYMFENTRA
Entyvio hatte ich auch, war auch nicht der bringer. Remsima is btw Infliximab
October 9, 2026 at 9:32 PM
Entyvio hatte ich auch, war auch nicht der bringer. Remsima is btw Infliximab
Oder ein Infliximab?
October 9, 2026 at 9:25 PM
Oder ein Infliximab?
And in a long-term follow-up analysis, @dr-james-lee.bsky.social and collaborators found that early intensive treatment—or “top-down” therapy using infliximab plus an immunomodulator—of Crohn’s disease was associated with reduced disease progression, hospitalization and need for abdominal surgery.
Early ‘top-down’ therapy reduces Crohn’s disease complications
American Gastroenterological Association's official newspaper
news.gastro.org
October 8, 2026 at 4:05 PM
And in a long-term follow-up analysis, @dr-james-lee.bsky.social and collaborators found that early intensive treatment—or “top-down” therapy using infliximab plus an immunomodulator—of Crohn’s disease was associated with reduced disease progression, hospitalization and need for abdominal surgery.
🏥 La sanidad madrileña mueve más de 6 millones en contratos: de la vacuna intranasal infantil al Infliximab 💉
https://boesinpaja.es/article/la-sanidad-madrilena-mueve-mas-de-6-millones-en-contratos-de-la-vacuna-intranasal-infantil-al-infliximab-2069024
#Fuenlabrada #Madrid
https://boesinpaja.es/article/la-sanidad-madrilena-mueve-mas-de-6-millones-en-contratos-de-la-vacuna-intranasal-infantil-al-infliximab-2069024
#Fuenlabrada #Madrid
October 7, 2026 at 4:13 AM
🏥 La sanidad madrileña mueve más de 6 millones en contratos: de la vacuna intranasal infantil al Infliximab 💉
https://boesinpaja.es/article/la-sanidad-madrilena-mueve-mas-de-6-millones-en-contratos-de-la-vacuna-intranasal-infantil-al-infliximab-2069024
#Fuenlabrada #Madrid
https://boesinpaja.es/article/la-sanidad-madrilena-mueve-mas-de-6-millones-en-contratos-de-la-vacuna-intranasal-infantil-al-infliximab-2069024
#Fuenlabrada #Madrid
Bad for seeing stuff at concerts. Great for infliximab dosing.
October 5, 2026 at 11:15 PM
Bad for seeing stuff at concerts. Great for infliximab dosing.
Infliximab for Drug-Induced Acute Interstitial Nephritis - Kidney International Case Reports www.kicasereports.org/article/S311...
More from the March issue
@kdjhaveri.bsky.social et al
More from the March issue
@kdjhaveri.bsky.social et al
Infliximab for Drug-Induced Acute Interstitial Nephritis
Acute interstitial nephritis (AIN) is a frequent cause of acute kidney injury (AKI)
and is commonly drug-induced. Corticosteroids are widely used for treatment; however,
outcomes in cases with incompl...
www.kicasereports.org
October 5, 2026 at 12:10 AM
Infliximab for Drug-Induced Acute Interstitial Nephritis - Kidney International Case Reports www.kicasereports.org/article/S311...
More from the March issue
@kdjhaveri.bsky.social et al
More from the March issue
@kdjhaveri.bsky.social et al
Covid booster in my left arm, flu jab in my right, infliximab self-inject into my left leg tonight.
When I go to bed, I'll only have one limb which hasn't been stabbed. And the big toe on that leg's been screaming at me for days for having the audacity to want to walk.
Winning at autoimmune. 😂
When I go to bed, I'll only have one limb which hasn't been stabbed. And the big toe on that leg's been screaming at me for days for having the audacity to want to walk.
Winning at autoimmune. 😂
Woody from Toy Story: Injured
Alt: Woody from Toy Story: sits on a shelf, legs dangling, books and toys around him. He uses one arm to lift the other then let's go and watches as it drops, limply.
static.klipy.com
October 3, 2026 at 10:00 AM
Covid booster in my left arm, flu jab in my right, infliximab self-inject into my left leg tonight.
When I go to bed, I'll only have one limb which hasn't been stabbed. And the big toe on that leg's been screaming at me for days for having the audacity to want to walk.
Winning at autoimmune. 😂
When I go to bed, I'll only have one limb which hasn't been stabbed. And the big toe on that leg's been screaming at me for days for having the audacity to want to walk.
Winning at autoimmune. 😂
Previous treatment with #adalimumab independently predicts lower #infliximab trough levels at the time of endoscopic remission in pediatric #Crohn disease patients. @crohnscolitisfdn.bsky.social
https://www.gastroenterologyadvisor.com/news/pediatric-crohn-disease-endoscopic-remission-infliximab/
https://www.gastroenterologyadvisor.com/news/pediatric-crohn-disease-endoscopic-remission-infliximab/
Prior Adalimumab Exposure Affects Infliximab Treatment in Pediatric Crohn Disease
Endoscopic remission in pediatric Crohn disease occurred at lower infliximab trough levels among patients with previous adalimumab exposure.
www.gastroenterologyadvisor.com
October 2, 2026 at 10:46 PM
Previous treatment with #adalimumab independently predicts lower #infliximab trough levels at the time of endoscopic remission in pediatric #Crohn disease patients. @crohnscolitisfdn.bsky.social
https://www.gastroenterologyadvisor.com/news/pediatric-crohn-disease-endoscopic-remission-infliximab/
https://www.gastroenterologyadvisor.com/news/pediatric-crohn-disease-endoscopic-remission-infliximab/
🛡️ Immunogenicity does not compromise outcomes with subcutaneous #infliximab
🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status
Find out more in this UEG Journal article:
👉 https://bit.ly/3UESgZp
🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status
Find out more in this UEG Journal article:
👉 https://bit.ly/3UESgZp
October 2, 2026 at 4:30 AM
🛡️ Immunogenicity does not compromise outcomes with subcutaneous #infliximab
🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status
Find out more in this UEG Journal article:
👉 https://bit.ly/3UESgZp
🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status
Find out more in this UEG Journal article:
👉 https://bit.ly/3UESgZp
Ophthopedia Update: Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report: .
Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report
.
dlvr.it
September 27, 2026 at 10:21 AM
Ophthopedia Update: Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report: .
Jab day for @crohnscolitisfdn.bsky.social @crohnsandcolitisau.bsky.social infliximab working a treat.
September 25, 2026 at 7:03 PM
Jab day for @crohnscolitisfdn.bsky.social @crohnsandcolitisau.bsky.social infliximab working a treat.
🧭 #Ustekinumab offers a safety advantage after #vedolizumab failure in #UC
🔸 Similar remission rates with infliximab, anti-TNF SC & ustekinumab
🔸 Fewer adverse events and treatment discontinuations with ustekinumab
Read the full article in UEG Journal:
👉 https://bit.ly/4gPXeKa
🔸 Similar remission rates with infliximab, anti-TNF SC & ustekinumab
🔸 Fewer adverse events and treatment discontinuations with ustekinumab
Read the full article in UEG Journal:
👉 https://bit.ly/4gPXeKa
September 25, 2026 at 5:45 AM
🧭 #Ustekinumab offers a safety advantage after #vedolizumab failure in #UC
🔸 Similar remission rates with infliximab, anti-TNF SC & ustekinumab
🔸 Fewer adverse events and treatment discontinuations with ustekinumab
Read the full article in UEG Journal:
👉 https://bit.ly/4gPXeKa
🔸 Similar remission rates with infliximab, anti-TNF SC & ustekinumab
🔸 Fewer adverse events and treatment discontinuations with ustekinumab
Read the full article in UEG Journal:
👉 https://bit.ly/4gPXeKa
I get infusion therapy with infliximab and take methotrexate and also diclofenac as needed
I try to drink turmeric tea too to help and eat less sugar
I try to drink turmeric tea too to help and eat less sugar
September 23, 2026 at 11:53 PM
I get infusion therapy with infliximab and take methotrexate and also diclofenac as needed
I try to drink turmeric tea too to help and eat less sugar
I try to drink turmeric tea too to help and eat less sugar
Waiting for pharmacy to get my infliximab ready so doom scrolling it is
September 23, 2026 at 7:30 PM
Waiting for pharmacy to get my infliximab ready so doom scrolling it is
I'm on a biologic (infliximab, a TNF inhibitor) and I got the flu + COVID vaccines together the first week of September. Maybe I should have waited, but that was the best weekend for me.
Those whose immune systems are more vulnerable are at a higher risk of getting sick with and experiencing severe symptoms of flu, COVID-19, and RSV.
Epidemiologist @cmyeaton.bsky.social gives her recommendations for vaccines this respiratory virus season.
🎧 t.jh.edu/ZXy7pM
Epidemiologist @cmyeaton.bsky.social gives her recommendations for vaccines this respiratory virus season.
🎧 t.jh.edu/ZXy7pM
September 23, 2026 at 3:09 PM
I'm on a biologic (infliximab, a TNF inhibitor) and I got the flu + COVID vaccines together the first week of September. Maybe I should have waited, but that was the best weekend for me.
⚖️ #Subcutaneous infliximab achieves higher tissue drug levels in #IBD
🔸Higher serum & tissue infliximab levels vs #IV therapy
🔸Tissue levels correlated with sustained remission and predicted outcomes better than serum levels
Read the article in UEG Journal:
👉 https://bit.ly/4yuoyoB
🔸Higher serum & tissue infliximab levels vs #IV therapy
🔸Tissue levels correlated with sustained remission and predicted outcomes better than serum levels
Read the article in UEG Journal:
👉 https://bit.ly/4yuoyoB
September 18, 2026 at 7:03 AM
⚖️ #Subcutaneous infliximab achieves higher tissue drug levels in #IBD
🔸Higher serum & tissue infliximab levels vs #IV therapy
🔸Tissue levels correlated with sustained remission and predicted outcomes better than serum levels
Read the article in UEG Journal:
👉 https://bit.ly/4yuoyoB
🔸Higher serum & tissue infliximab levels vs #IV therapy
🔸Tissue levels correlated with sustained remission and predicted outcomes better than serum levels
Read the article in UEG Journal:
👉 https://bit.ly/4yuoyoB
Absolutely, I think the lit here mostly helps with providing a sense of how aggressive to treat it (very, it's brain tissue being choked after all) as well as what steroid sparing agents seem to work best (Methotrexate, mebbe with infliximab)
September 15, 2026 at 1:19 PM
Absolutely, I think the lit here mostly helps with providing a sense of how aggressive to treat it (very, it's brain tissue being choked after all) as well as what steroid sparing agents seem to work best (Methotrexate, mebbe with infliximab)
Oder halt nach Biologika. Also was mit Risankizumab oder ein Infliximab. Die haben zwar schon einen rechten impact aber helfen halt oft gut. (Kommt aber immer auf die eigene med. Geschichte an)
Aber für eine akut Sache wäre Kortison auch was.
Aber für eine akut Sache wäre Kortison auch was.
September 13, 2026 at 11:11 AM
Oder halt nach Biologika. Also was mit Risankizumab oder ein Infliximab. Die haben zwar schon einen rechten impact aber helfen halt oft gut. (Kommt aber immer auf die eigene med. Geschichte an)
Aber für eine akut Sache wäre Kortison auch was.
Aber für eine akut Sache wäre Kortison auch was.
The PROFILE trial of top-down infliximab in Crohn's disease has reported dramatic results over 5 years of follow up. My thoughts here: barrettlab.eu/blog/profile/
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Using the drugs we have more effectively | Barrett Lab @ University of Helsinki
The readout of the PROFILE trial after 5 years shows dramatic benefit from top-down treatment for Crohn's disease.
barrettlab.eu
September 12, 2026 at 1:17 PM
The PROFILE trial of top-down infliximab in Crohn's disease has reported dramatic results over 5 years of follow up. My thoughts here: barrettlab.eu/blog/profile/
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Gaaanz am Anfang 2020 hat man auf der ITS sogar Infliximab bei akuten Cov Pat probiert... hat sich zwar nicht durchgesetzt, war aber (klinische Anekdote) auch nicht das "allerschlechteste" gegen die überschießende Immunreaktion.
September 11, 2026 at 4:00 PM
Gaaanz am Anfang 2020 hat man auf der ITS sogar Infliximab bei akuten Cov Pat probiert... hat sich zwar nicht durchgesetzt, war aber (klinische Anekdote) auch nicht das "allerschlechteste" gegen die überschießende Immunreaktion.
They’re putting infliximab into my ailing body because I have Crohns!
September 8, 2026 at 3:13 PM
They’re putting infliximab into my ailing body because I have Crohns!
The likelihood of treatment-induced hidradenitis suppurativa varied by more than twofold across different types of biologic therapies for psoriasis, an analysis of a large clinical database showed.
https://www.medpagetoday.com/dermatology/psoriasis/122870
https://www.medpagetoday.com/dermatology/psoriasis/122870
Risk of Paradoxical Hidradenitis Suppurativa in Psoriasis Varies by Biologic Agent
Infliximab and adalimumab had the highest risk, risankizumab and guselkumab the lowest
www.medpagetoday.com
September 2, 2026 at 8:33 PM
The likelihood of treatment-induced hidradenitis suppurativa varied by more than twofold across different types of biologic therapies for psoriasis, an analysis of a large clinical database showed.
https://www.medpagetoday.com/dermatology/psoriasis/122870
https://www.medpagetoday.com/dermatology/psoriasis/122870